Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target
BTIG maintained a Buy rating and $26.00 price target on Oric Pharmaceuticals (ORIC) after its Q3 earnings. The stock trades at $7.52, near its 52-week low. The company reported positive data for rinzimetostat and enozertinib, with key trials expected in 2027. ORIC has $345M in cash, sufficient for operations into 2028. Stifel also raised its price target to $18.
How this was made
The 30-second read
Why it matters
The piece frames ORIC’s Q3 earnings follow-through as de-risking via clinical data and pushes major trial milestones into 2027, while highlighting a cash position intended to fund operations into 2H 2028.
Market read
For ORIC traders, the actionable takeaway is the reinforced catalyst calendar (Q1 2027 topline, H1 2027 phase 3 initiation) and the cash runway supporting funding through 2H 2028.
What to watch
The article emphasizes cash runway into 2H 2028, but does not quantify burn rate or dilution risk; traders may need to monitor financing needs if trial timelines slip.
Background
Oric Pharmaceuticals is advancing rinzimetostat (metastatic castration-resistant prostate cancer) and enozertinib (EGFR atypical NSCLC), with MEVPRO-1 and Redwood-1 as key upcoming milestones.
Ticker impact
BTIG maintained a Buy on ORIC after its Q3 earnings, citing rinzimetostat progression-free survival data and updated MEVPRO-1 and Redwood-1 timelines.
Likely upward bias as traders price in 2027 topline and phase 3 initiation milestones referenced in the earnings follow-through.
The article ties ORIC’s own reported clinical data and cash runway into specific 2027 catalyst windows, but it is still an analyst-maintenance writeup rather than a fresh primary disclosure beyond the earnings-linked update.
Market effects
Adds incremental sentiment to oncology biotech names tied to prostate cancer and EGFR atypical NSCLC, but impact is company-specific.
Limited, US small/mid-cap biotech sentiment only.
Low, as the catalysts are company-specific clinical timelines and conference-linked data.
Counterpoint
Timeline shifts (MEVPRO-1 to Q1 2027, Redwood-1 into H1 2027) can delay near-term valuation catalysts, leaving the stock vulnerable to trial execution risk.
Key entities
- companyOric Pharmaceuticals
NASDAQ-listed biotech advancing rinzimetostat and enozertinib; subject of BTIG Buy and $26 target after Q3 earnings.
- analyst_firmBTIG
Maintained Buy rating and $26 price target on ORIC.
- analyst_firmStifel
Raised price target to $18 and maintained Buy rating on ORIC.

